the importance of the Match-Point Module
With a vision of continuously increasing access to clinical trials it very important to feature an always UpToDate database of ongoing clinical trials in which patients can participate.
Match-Point is this database and the main and central module of the Trial Eye infrastructure. Match-Point is the start of every patient / clinical trial match and all the other Trial Eye modules and features help sponsors and study sites to startup clinical trials fast at that location where the patient is in need of an extra treatment option.
Powered by iClusion
iClusion's mission is to provide oncologists and their patients with easy, reliable and standardized access to clinical trials through specially designed platforms. The professional Trial Eye platform for research professionals makes it possible for drug developers and physicians to conduct clinical research close to the patient. The public Heyleys platform makes it possible for patients to easily find clinical research and to discuss participation with the treating physician. While Heyleys means extra treatment opportunities for patients, Trial Eye means:
- More treatment options
- Increased access to innovative drugs
- Maintain patient relationships
- Transparency in clinical trials
- Participation in more trials
- Quality of Care
- Faster market authorizations within regulatory compliance
For study sponsors
- Shorter duration of trials
- Shorter time to market
Frequently Asked Questions
CRO’s often offer many more clinical trial services (like protocol writing and national approvals) but their main and most important task remains data capture, monitoring and analysis. Once a trial is locally approved initiation will take place by the sponsor or CRO.
Once a patient is matched and informed, the patient is randomized and included by the sponsor or CRO within their systems and data capture, monitoring and analyzing is thus not done within the Trial Eye infrastructure.
Its patients’ profiles that will be linked to possible suitable trials. By studying the actual protocol the physician can then decide if the patient actually can be included and start the ICF procedure. The signed document will only be stored physically within the study site and/or digitally within the sponsor’s or CRO’s system. The Trial Eye infrastructure only provides a standardized procedure to access, start and monitor ICF procedures.
Each event of matching a patient will generate a unique Trial Eye event number that can be tracked on informing and routing towards the sponsor or CRO systems for randomization and/or inclusion.